Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1832 1
1843 1
1859 2
1868 1
1889 1
1923 1
1925 1
1929 1
1947 1
1948 1
1949 1
1950 1
1951 7
1952 5
1953 2
1955 1
1956 2
1957 1
1960 1
1961 3
1962 3
1963 1
1964 7
1965 5
1966 11
1967 10
1968 4
1969 11
1970 5
1971 13
1972 14
1973 11
1974 14
1975 17
1976 13
1977 21
1978 11
1979 22
1980 22
1981 11
1982 16
1983 10
1984 10
1985 17
1986 23
1987 21
1988 29
1989 30
1990 31
1991 33
1992 17
1993 28
1994 33
1995 32
1996 30
1997 27
1998 29
1999 35
2000 40
2001 33
2002 44
2003 45
2004 59
2005 70
2006 72
2007 77
2008 94
2009 111
2010 115
2011 105
2012 121
2013 140
2014 154
2015 153
2016 151
2017 170
2018 166
2019 161
2020 179
2021 177
2022 149
2023 154
2024 155
2025 121

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,394 results

Results by year

Filters applied: . Clear all
Page 1
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: shaw at. J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31. J Clin Oncol. 2024. PMID: 38819031 Free PMC article. Clinical Trial.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Fluids in the ICU: which is the right one?
Mayerhöfer T, Shaw AD, Wiedermann CJ, Joannidis M. Mayerhöfer T, et al. Among authors: shaw ad. Nephrol Dial Transplant. 2023 Jun 30;38(7):1603-1612. doi: 10.1093/ndt/gfac279. Nephrol Dial Transplant. 2023. PMID: 36170962 Free PMC article. Review.
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, Riley AK, Wilson JJ, Mao YQ, Huang RP, Banwait MK, Ho J, Crowther GS, Hariri LP, Heist RS, Kodack DP, Pinello L, Shaw AT, Mino-Kenudson M, Hata AN, Sequist LV, Benes CH, Niederst MJ, Engelman JA. Hu H, et al. Among authors: shaw at. Cancer Cell. 2021 Nov 8;39(11):1531-1547.e10. doi: 10.1016/j.ccell.2021.09.003. Epub 2021 Oct 7. Cancer Cell. 2021. PMID: 34624218 Free PMC article.
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Ravi A, et al. Among authors: shaw at. Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6. Nat Genet. 2023. PMID: 37024582 Free PMC article.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS, Hata AN. Isozaki H, et al. Among authors: shaw at. Nature. 2023 Aug;620(7973):393-401. doi: 10.1038/s41586-023-06303-1. Epub 2023 Jul 5. Nature. 2023. PMID: 37407818 Free PMC article.
Parallel control of cold-triggered adipocyte thermogenesis by UCP1 and CKB.
Rahbani JF, Bunk J, Lagarde D, Samborska B, Roesler A, Xiao H, Shaw A, Kaiser Z, Braun JL, Geromella MS, Fajardo VA, Koza RA, Kazak L. Rahbani JF, et al. Among authors: shaw a. Cell Metab. 2024 Mar 5;36(3):526-540.e7. doi: 10.1016/j.cmet.2024.01.001. Epub 2024 Jan 24. Cell Metab. 2024. PMID: 38272036 Free article.
Response and Resistance to RAS Inhibition in Cancer.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. Ebright RY, et al. Among authors: shaw at. Cancer Discov. 2025 Jul 3;15(7):1325-1349. doi: 10.1158/2159-8290.CD-25-0349. Cancer Discov. 2025. PMID: 40293709 Review.
3,394 results